A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination with Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma

Study identifier:D4190C00022

ClinicalTrials.gov identifier:NCT02519348

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

A Study of Safety, Tolerability, and Clinical Activity of Durvalumab and Tremelimumab Administered as Monotherapy, or Durvalumab in Combination with Tremelimumab or Bevacizumab in Subjects with Advanced Hepatocellular Carcinoma

Medical condition

Hepatocellular Carcinoma

Phase

Phase 2

Healthy volunteers

No

Study drug

-

Sex

All

Actual enrollment

433

Study type

Interventional

Age

18 Years - 99 Years

Date

Study Start Date: 19 Oct 2015
Primary Completion Date: 06 Nov 2020
Estimated Study Completion Date: 29 Dec 2023

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Oct 2022 by MedImmune, LLC

Sponsors

MedImmune, LLC

Collaborators

-

Inclusion and exclusion criteria